Primary splenic lymphoma: Current diagnostic trends

Sachin B Ingle, Chitra R Hinge (Ingle)

Sachin B Ingle, Department of Pathology, MIMSR Medical College, Latur, Maharashtra 4132512, India

Chitra R Hinge (Ingle), Department of Physiology, MIMSR Medical College, Latur, Maharashtra 4132512, India

Author contributions: Ingle SB prepared the first draft of the manuscript; Hinge (Ingle) CR critically revised the manuscript, added intellectual content and approved the final draft of the manuscript.

Conflict-of-interest statement: All the authors hereby declare that they have no any conflicts of interests.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Correspondence to: Sachin B Ingle, Professor, Department of Pathology, MIMSR Medical College, Ambajogai Road, vishwanathpuram, Latur, Maharashtra 4132512, India. dr.sachiningle@gmail.com
Telephone: +91-2382-227424
Fax: +91-2382-228939

Received: March 13, 2016
Peer-review started: March 14, 2016
First decision: April 20, 2016
Revised: October 9, 2016
Accepted: October 22, 2016
Article in press: October 24, 2016
Published online: December 16, 2016

Abstract
The primary splenic lymphoma is extremely uncommon, can present with grave complications like hypersplenism and splenic rupture. In view of vague clinical presentation, it is difficult to arrive at the diagnosis. In such circumstances, histopathological diagnosis is very important. A precise diagnosis can only be made on histopathology and confirmed on immunohistochemistry. Emergency splenectomy is preferred as an effective therapeutic and diagnostic tool in cases with giant splenomegaly. Core biopsy is usually not advised due to a high risk of post-core biopsy complications in view of its high vascularity and fragility. Aim behind highlighting the topic is to specify that core biopsy/ fine needle aspiration cytology can be used as an effective diagnostic tool to arrive at correct diagnosis to prevent untoward complications related to disease and treatment. Anticoagulation therapy is vital after splenectomy to avoid portal splenic vein thrombosis.

Key words: Splenic lymphoma; Biopsy; Immunohistochemistry

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Primary splenic lymphoma is a rare entity, has vague clinical presentation and can present with grave complications like hypersplenism and splenic rupture. In such circumstances, core biopsy/fine needle aspiration cytology can hit the correct pathological diagnosis. Emergency splenectomy is an effective therapeutic and diagnostic tool in cases with massive splenomegaly with features of hypersplenism.

Ingle SB, Hinge (Ingle) CR. Primary splenic lymphoma: Current diagnostic trends. World J Clin Cases 2016; 4(12): 385-389
Available from: URL: http://www.wjgnet.com/2307-8960/full/v4/i12/385.htm DOI: http://dx.doi.org/10.12998/wjcc.v4.i12.385

INTRODUCTION
Primary splenic lymphoma (PSL) is very unusual
entities if strict diagnostic criteria are applied\(^{[1]}\). As per previous studies the final diagnosis of PSL should be made only when the disease is limited to spleen or involving hilar lymph nodes without any recurrence after splenectomy\(^{[1-4]}\). In patients with PSL, therapeutic splenectomy is to be done. However, presently ultrasound guided core biopsy is a safe and efficient diagnostic investigation, can be used routinely. Therapeutic splenectomy is to be followed by anticoagulation therapy and chemotherapy\(^{[5]}\).

**EPIDEMIOLOGY**

**Incidence**

PSL is a rare neoplasm of the spleen, probably comprising less than 2% of all the lymphomas\(^{[6,7]}\) and 1% of all the non-Hodgkin’s lymphomas\(^{[2,8-10]}\).

**Types**

There are two main types: (1) splenic lymphoma with circulating villous lymphocytes\(^{[6]}\), and (2) marginal zone splenic lymphoma originating from a peculiar splenic B-cell structure separated by the mantle zone.

**CLINICAL PRESENTATIONS**

**Nonspecific symptoms**

Clinical presentations of nonspecific symptoms are weight loss, weakness, fever, and lower upper quadrant pain or discomfort due to enlarged spleen.

**Specific symptoms**

Clinical presentations of specific symptoms are mainly due to invasion of lymphoma cells in to adjacent organs stomach, pancreas, diaphragm, colon, or mesentery\(^{[11-16]}\).

**Hematological parameters**

Cytopaenia can also be a presenting feature\(^{[7]}\). The complete blood count and peripheral smear (PS) findings are mostly unremarkable\(^{[17]}\). Elevation of ESR may be noted\(^{[7]}\).

**Other presentations**

PSL presenting as splenic abscess although uncommon, is associated with high morbidity and death rates due to delayed diagnosis and management\(^{[18]}\). Due to vague presentation, the clinical diagnosis is difficult\(^{[19]}\). Splenic lymphomas usually present as space occupying solid lesions and when present as splenic abscesses are usually encountered in patients with underlying disorders, including infections, emboli, trauma, recent surgery, malignant hematologic conditions and immuno-suppression\(^{[20]}\).

**DIAGNOSTIC APPROACH**

The nonspecific clinical presentation of PSL creates the real diagnostic dilemma.

**Reference criteria for diagnosis/staging PSL**

Dasgupta et al\(^{[1]}\) reported that Lymphoma restricted to the spleen and hilar lymph nodes. Further confirmed following a 6-mo relapse-free period following splenectomy. Skarin et al\(^{[21]}\) reported that lymphoma with splenic involvement in which splenomegaly is the dominant feature. Dachman et al\(^{[14]}\) reported that splenic lesions with hypodensity on contrast enhanced Computed tomography scans or lesions with hypoechogenicity on ultrasound (USG) studies. Ahmann et al\(^{[11]}\) reported that stage I refers to disease confined to the spleen; Stage II refers to splenic involvement along with hilar lymph nodes; Stage III refers to extra-splenic nodal or hepatic involvement.

**Peripheral blood smear evaluation**

Most of the patients we can reveal neoplastic lymphoid cells on peripheral blood smear, i.e., hairy cells, prolymphocytes, villous lymphocytes, basophilic villous lymphocytes, etc., which may raise the suspicion of neoplastic lymphoid disease in the mind of pathologist (Figure 1).

**Biopsy**

Core biopsy/fine needle aspiration cytology (FNAC) are traditionally not recommended in view of high fragility of splenic tissue leading to hemorrhagic complications. However, currently it can be used as a routine diagnostic test\(^{[22]}\).

**In diffuse large B cell lymphoma:** Microscopy predominantly shows monotonous population of large neoplastic lymphoid cells with large areas of necrosis\(^{[5]}\). The individual cells essentially demonstrated a large atypical nucleus, irregular nuclear borders with vesicular chromatin and prominent nuclei. Histopathological examination reported as Non-Hodgkin’s Lymphoma of diffuse large B cell phenotype\(^{[5]}\) (Figure 2).

**Hairy cell leukemia:** Shows the small to medium sized lymphocytic infiltrate more clearly. Round to kidney-shaped with abundant clear cytoplasm are usually revealed (Figure 3).

**Marginal zone splenic lymphoma:** Splenic white pulp reactive germinal centres show small neoplastic lymphoid cells almost replacing the mantle zone with occasional large blast like malignant lymphoid cells. Other points we have to reveal are epithelial histocytes, sinus invasion, and plasmacytic differentiation of proliferating cells\(^{[5]}\) (Figure 4).

**PSL (follicular type):** It is neoplastic proliferation of follicle center B-cells, i.e., centrocytes and centroblasts exhibiting follicular pattern (Figure 5).

**Immunohistochemistry**

Histopathology report is to be confirmed by IHC. The tumor cells are immunopositive for B cell markers, e.g.,
CD 20 and immunonegative for T cell markers (Figure 6).

**B cell lymphoma:** B cell lymphoma-2 (BCL-2) immuno-reactivity is useful to differentiate malignant lymphoma (BCL-2 positive) from reactive (BCL-2 negative) B cells in the marginal zone (Figure 7).
Diagnostic imaging

US imaging of the abdomen and whole-body computed tomography are to be done in each and every case with splenomegaly. The B mode USG determines the actual size of spleen and computed tomography confirms the involvement of hilar lymph nodes [23, 24].

DIAGNOSTIC AND THERAPEUTIC SPLENECTOMY

The previous workers suggested splenectomy as an effective diagnostic and therapeutic tool [25, 26]. It has morbidity and mortality rates accounting for approximately 12% and less than 1%, respectively [27]. Now a days, laparoscopic splenectomy can be used as a safe and efficient method, reducing both the mortality and morbidity significantly [28]. In this the distortion of the samples should be strictly avoided.

Needle core biopsy is more efficient and safe and can be used in high risk patients also. Previous studies [29, 30] concluded that splenic needle biopsy has low complication rates with high diagnostic utility. Recently, laparoscopic splenectomy has been often used for splenic masses because of fewer complications and since it is rather appropriate for moderate splenomegaly [30, 31].

Echo-guided splenic biopsy and FNAC are effective in peripherally located lesions [32]. Splenic DLBCLs are clinically aggressive neoplasms. So, line of treatment of such SLs should be same as DLBCLs [33]. Splenic form of the micronodular T-cell/histiocyte-rich DBLCL subtype presents with micronodules in the spleen with involvement of bone marrow or other extranodal sites [34, 35].

Gastroesophageal reflux is associated with benign peptic ulcer disease, gastric Crohn’s disease, gastric adenocarcinoma, and primary gastric and splenic lymphomas. There occurs hemorrhage due to erosion by primary splenic lesion in the stomach. Upper intestinal hemorrhage can be successfully treated with splenic artery embolization, followed by splenectomy and gastric resection [35].

To conclude, splenic needle biopsy or core biopsy can be used as an effective diagnostic tool now days to hit the correct histological diagnosis to avoid untoward complications related to disease and treatment in search of accurate pathological diagnosis.

REFERENCES

1. Das Gupta T, Coombes B, Brasfield rd. primary malignant neoplasms of the spleen. Surg Gynecol Obstet 1965; 120: 947-960 [PMID: 14269844]
2. Cavanna L, Artioli F, Vallisa D, Di Donato C, Bertè R, Carapezzi C, Foroni R, Del Vecchio C, Lo Monaco B, Prati R. Primary lymphoma of the spleen. Report of a case with diagnosis by fine-needle guided biopsy. Haematologica 1995; 80: 241-243 [PMID: 7672717]
3. Harris NL, Aisenberg AC, Meyer JE, Ellman L, Elman A. Diffuse large cell (histiocytic) lymphoma of the spleen. Clinical and pathologic characteristics of ten cases. Cancer 1984; 54: 2460-2467 [PMID: 6388805 DOI: 10.1002/1097-0142(19841201)54:11<2460::AID-CNCR2820541125>3.0.CO;2-K]
4. Burke JS. Surgical pathology of the spleen: an approach to the differential diagnosis of splenic lymphomas and leukemias. Part II. Diseases of the red pulp. Am J Surg Pathol 1981; 5: 681-694 [PMID: 7039375]
5. Ingle SB, Ingle CR. Splenic lymphoma with massive splenomegaly: Case report with review of literature. World J Clin Cases 2014; 2: 478-481 [PMID: 25232555 DOI: 10.12998/wjcc.v2.i9.478]
6. Gobbi PG, Grignani GE, Pozzetti U, Bertoloni D, Piersesca C, Montagna G, Ascarini E. Primary splenic lymphoma: does it exist? Haematologica 1994; 79: 286-293 [PMID: 7926983]
7. Healy NA, Connelly JB, Mahon S, O’ Riordan C, McAnena OJ.
Primary splenic lymphoma presenting with ascites. Rare Tumors 2011; 3: e25 [PMID: 21769324 DOI: 10.4081/rt.2011.e25]

8 Kraemer BB, Osborne BM, Butler JJ. Primary splenic presentation of malignant lymphoma and related disorders. A study of 49 cases. Cancer 1984; 54: 1606-1619 [PMID: 6548171 DOI: 10.1002/1097-0142(19841001)54:8<1606::AID-CNCR2820540823-3.0.CO;2-5]

9 Keoho J, Straus DJ. Primary lymphoma of the spleen. Clinical features and outcome after splenectomy. Cancer 1988; 62: 1433-1438 [PMID: 3416282 DOI: 10.1002/1097-0142(19881001)62:7<1433::AID-CNCR2820620703-3.0.CO;2-V]

10 Falk S, Stutte HJ. Primary malignant lymphomas of the spleen. A morphologic and immunohistochemical analysis of 17 cases. Cancer 1990; 66: 2612-2619 [PMID: 2224201 DOI: 10.1002/1097-0142(19901215)96:12<2612::AID-CNCR2820661225-3.0.CO;2-Q]

11 Ahmann DL, Kiely JM, Harrison EG, Payne WS. Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer 1966; 19: 461-469 [PMID: 5327041 DOI: 10.1002/1097-0142(19660419:4<461::AID-CNCR2820190402-3.0.CO;2-X]

12 Kim KH, Cho CK, Choo SW, Kim HJ, Kim KS. Primary lymphoma of the spleen - a case report. Korean J Surg 1997; 52: 912-917

13 Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma survival and diagnostic factors. Yonsei Med J 1997; 38: 270-284 [PMID: 9409190 DOI: 10.3349/ymj.1997.38.5.270]

14 Dachman AH, Buck JL, Krishnan J, Aguilara NS, Buetow PC. Primary non-Hodgkin’s splenic lymphoma. Clin Radiol 1998; 53: 137-142 [PMID: 9502091 DOI: 10.1016/S0009-9260(98)80061-5]

15 Xiros N, Economopoulos T, Christodoulidis C, Dervenoulas J, Papageorgiou E, Mellou S, Stylianos S, Tsirigotis P, Raptis SA. Splenectomy in patients with malignant non-Hodgkin’s lymphoma. Eur J Haematol 2000; 64: 145-150 [PMID: 10997879 DOI: 10.1046/j.1600-0609.2000.90079.x]

16 Brox A, Bishinsky JI, Berry G. Primary non-Hodgkin lymphoma of the spleen. Am J Hematol 1991; 38: 95-100 [PMID: 1951314 DOI: 10.1002/ajh.2830380205]

17 Izzo L, Binda B, Boschetto A, Carmanico L, Galati G, Fior E, Marini M, Mele LL, Stasolla A. Primary Splenic Lymphoma; the diagnostic and therapeutic value of splenectomy. Haematologica 2002; 87: ECR 20

18 Agrawal SC, Bharucha MA, Deo A, Velling K. Post surgical diagnosis of primary DBLCB presenting as Splenic abscess. Austral - Asian Journal of Cancer 2012; 11: 217-220

19 Konstantioudou E, Mastoraki A, Papakoloua I, Sarkorafas G, Safiroleas M. Surgical approach of primary splenic lymphoma: report of a case and review of the literature. Indian J Hematol Blood Transfus 2009; 25: 120-124 [PMID: 23100989 DOI: 10.1007/s12288-009-0025-3]

20 Thanos I, Dialaina T, Papaioannou G, Nikita A, Koutronvelis H, Kelekis DA. Percutaneous CT-guided drainage of splenic abscess. AJR Am J Roentgenol 2002; 179: 629-632 [PMID: 12185032 DOI: 10.2214/ajr.179.3.1790629]

21 Skarin AT, Davey FR, Moloney WC. Lymphosarcoma of the spleen. Results of diagnostic splenectomy in 11 patients. Arch Intern Med 1971; 127: 259-265 [PMID: 5101153]

22 López J, Del Cura JL, De Larrinoa AF, Gorriño O, Zapala R, Bilbao FJ. Role of ultrasound-guided core biopsy in the evaluation of spleen pathology. APMS 2006; 114: 492-499 [PMID: 16907854 DOI: 10.1111/j.1600-0463.2006.apms.378.x]

23 Lamb PM, LUND A, Kanagasabay RR, Martin A, Webb JA, Reznik RH. Spleen size: how well do linear ultrasound measurements correlate with three-dimensional CT volume assessments? Br J Radiol 2002; 75: 573-577 [PMID: 12145129 DOI: 10.1259/bjr.75.895.750573]

24 Peddu P, Shah M, Sidhu PS. Splenic abnormalities: a comparative review of ultrasound, microbubble-enhanced ultrasound and computed tomography. Clin Radiol 2004; 59: 777-792 [PMID: 15351243 DOI: 10.1016/j.crad.2004.01.007]

25 Iannitti E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011; 117: 2585-2595 [PMID: 21119113 DOI: 10.1182/blood-2009-09-271437]

26 Vander Walt JD. Lymphomas in the bone marrow. Diag Histopathol 2010; 16: 125-142 [DOI: 10.1016/j.mhpdp.2009.12.008]

27 Baccarani U, Terrossi G, Donini A, Zaja F, Bressolada F, Baccarani M. Splenectomy in hematology. Current practice and new perspectives. Haematologica 1999; 84: 431-436 [PMID: 10329922]

28 Grahm SW, Alvarez J, Kirkwood K. Trends in laparoscopic splenectomy for massive splenomegaly. Arch Surg 2006; 141: 755-761; discussion 761-762 [PMID: 16924082 DOI: 10.1001/archsurg.141.8.755]

29 Tam A, Krishnamurthy S, Pillsbury EP, Ensor JE, Gupta S, Marthy R, Ahrrar K, Wallace MJ, Hicks ME, Madoff DC. Percutaneous image-guided splenic biopsy in the oncology patient: an audit of 156 consecutive cases. J Vasc Interv Radiol 2008; 19: 80-87 [PMID: 18192471 DOI: 10.1016/j.jvir.2007.08.025]

30 Gómez-Rubio M, López-Cano A, Rendón P, Muñoz-Benvenynt A, Macías M, Garre C, Segura-Cabral JM. Safety and diagnostic accuracy of percutaneous ultrasound-guided biopsy of the spleen: a multicenter study. J Clin Ultrasound 2009; 37: 445-450 [PMID: 19552827 DOI: 10.1002/jca.20608]

31 Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007; 110: 29-36 [PMID: 17360935 DOI: 10.1182/blood-2007-01-041871]

32 Tessier DJ, Pierce RA, Brunt LM, Halpin VJ, Eagon JC, Frisella MM, Czernecki S, Matthews BD. Laparoscopic splenectomy for splenic masses. Surg Endosc 2008; 22: 2062-2066 [PMID: 18246392 DOI: 10.1007/s00464-008-9748-8]

33 Shimizu I, Ichikawa N, Yotsumoto M, Sunii M, Ueno M, Kobayashi H. Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab. Intern Med 2007; 46: 1381-1386 [PMID: 17827836 DOI: 10.2169/internalmedicine.46.0066]

34 Kan E, Levy I, Benharroch D. Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: effect of prior corticosteroid therapy. Virchows Arch 2009; 455: 337-341 [PMID: 19763612 DOI: 10.1007/s00428-009-0830-y]

35 Bird MA, Amjadi D, Behrens KE. Primary splenic lymphoma complicated by hematemesis and gastric erosion. South Med J 2002; 95: 941-942 [PMID: 12190240]

P- Reviewer: Chan EL, Liu QD S- Editor: Kong JX L- Editor: A E- Editor: Wu HL
